about
Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistanceEvaluation of the clinical microbiology profile of moxifloxacin.Fluoroquinolone drug class update.Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.Moxifloxacin safety: an analysis of 14 years of clinical data.Fluoroquinolone adverse effects and drug interactions.Activity of and resistance to moxifloxacin in Staphylococcus aureus.QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis.Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill StudiesEvaluation of Moxifloxacin-induced Biochemical Changes in MiceNewer fluoroquinolones in the treatment of acute exacerbations of COPDInteractions between warfarin and three commonly prescribed fluoroquinolones.Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.Cure of Q fever pneumonia with moxifloxacin: case report.Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.validated microbiological and HPLC methods for the determination of moxifloxacin in pharmaceutical preparations and human plasma.Simple and sensitive stability-indicating ion chromatography method for the determination of cyclopropylamine in nevirapine and moxifloxacin hydrochloride drug substancesActivities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia.Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.Penetration of moxifloxacin into rat mandibular bone and soft tissue.Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.Sinus tissue concentration of moxifloxacin after a single oral dose.Moxifloxacin-warfarin interaction: a series of five case reports.
P2860
Q34102811-CB9D1678-4705-49BA-94B2-BD9ADBF5D416Q34183540-D1842E16-D5E3-4396-96D6-48A4DDEAF0FEQ34231182-65A4A6CD-E258-4AEA-9648-F8B3BF11828EQ34240856-3DA8F0C6-ED24-4EC1-AACC-B3C2A485D09AQ34310568-C79A44CA-25C0-4FA3-9436-3EC939F7880AQ34408447-E99F49DE-748D-4BEC-9AC4-7E90DEF24C82Q34885313-457B1308-039E-459A-85DF-54AE8D61CC51Q35545104-9ABCB4DF-DA4F-41FD-AB2B-80A5E9F01DCFQ35909500-F60A3C59-8309-48CC-9413-6D9CCC809E97Q36039472-CD15FEE4-30C1-42CD-A866-DB98F2461AE3Q36865298-A5CC83B2-8F34-4CE2-BC56-48169BA9D141Q37018822-57BC919D-4D1D-45D5-B7D1-97CBE0A1B6A2Q37138850-E6BCCFFF-A51A-4879-9C93-1B1157E3A1ACQ38703330-CE1F659E-0127-44F0-B13A-A5F272D91EFBQ39476051-B90938F5-28F3-4721-8FC3-DA5FD41DBC9EQ40497592-5998D714-1BF6-4F9D-A60E-E45C13A3D7B5Q40621946-355E8FEE-008D-4193-823E-0E15DB37FBBCQ41853006-A26827AA-4E50-4464-91CC-7E3AC5111432Q42041774-B03546AC-A01F-462B-9723-B32BFD3008F0Q42111239-7A73CAA8-56AD-47D8-BBB3-C7816A4921EDQ42591462-612FBA93-F267-4B04-99F1-C23AD8F7834AQ43181838-7F43AA1A-796A-4712-BB82-698553386640Q43904283-E0CDBA7A-F48C-4EB9-86FD-B96D488C2C0DQ44075569-3B54EA7E-6063-4F6E-A61E-5C9CDAD68824Q44471902-FD65AA5A-7A23-4C70-BF3A-33D31E1547ADQ44782882-F5F0BE1D-6F51-4900-AA06-C0377D8A53B7Q45211734-5C05D243-08D6-4EFE-AC56-FDD7EF3E50A3
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Moxifloxacin.
@ast
Moxifloxacin.
@en
Moxifloxacin.
@nl
type
label
Moxifloxacin.
@ast
Moxifloxacin.
@en
Moxifloxacin.
@nl
prefLabel
Moxifloxacin.
@ast
Moxifloxacin.
@en
Moxifloxacin.
@nl
P1433
P1476
Moxifloxacin.
@en
P2093
Balfour JA
Wiseman LR
P304
363-73; discussion 374
P356
10.2165/00003495-199957030-00007
P577
1999-03-01T00:00:00Z
P6179
1023298604